CN102091070A - Rabeprazole sodium combined medicament and preparation process thereof - Google Patents
Rabeprazole sodium combined medicament and preparation process thereof Download PDFInfo
- Publication number
- CN102091070A CN102091070A CN2010106074231A CN201010607423A CN102091070A CN 102091070 A CN102091070 A CN 102091070A CN 2010106074231 A CN2010106074231 A CN 2010106074231A CN 201010607423 A CN201010607423 A CN 201010607423A CN 102091070 A CN102091070 A CN 102091070A
- Authority
- CN
- China
- Prior art keywords
- medicine
- leila
- bei
- composition
- azoles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides a rabeprazole sodium combined medicament and a preparation process thereof. The rabeprazole sodium combined medicament is characterized by comprising the following raw materials as components in proportion by weight: 5-10 of ilaprazole sodium, 20-30 of composition of reduced glutathione and hepatocyte growth-promoting factors in proportion by weight of 1:10, and 50-60 of diammonium glycyrrhizinate. According to a pharmaceutically allowable dose of rabeprazole sodium, pharmaceutical preparations in dosage forms of injection, lyophilized powder injection, enteric coated tablets, enteric coated capsules, spray and the like of the rabeprazole sodium combined medicament are respectively prepared for treating gastric ulcer.
Description
Technical field
The present invention relates to the composition of medicine and the preparation technology thereof of Bei Leila azoles sodium.
Background technology
Harmonization of the stomach duodenum mucosa has natural gastric acid and the erosive perfect mechanism of pepsin resisted, but when helicobacter pylori and nonsteroidal anti-inflammatory drug damage it, causes peptic ulcer disease to take place.Australia scholar Warren and Marshall disclose this cause of disease, and H is arranged
2The receptor antagonist medicine is treated effectively, after 22 years, and two people and obtain Nobel Prize in medicine in 2005.Have the proton pump inhibitor medicine to be used for the treatment of peptic ulcer disease the eighties in last century again, compares H
2The inhibitor for treating effect is more powerful and lasting.Bei Leila azoles sodium is exactly typically to represent medicine, is one of line choice drug of treatment peptic ulcer disease at present.But, the Bei Leila azoles sodium lyophilized injection of prior art, still adopt the former technology of active carbon desuperheating in the preparation production, cause active carbon fine particle, heavy metal ion all to remain in the medicinal liquid, bring into during intravenous drip in the blood of human body, bring the infringement of medicine, and the present invention discovers health, pyrogen in the activated carbon adsorption medicinal liquid is not thorough, and reason is: the one, and it is below 0.08% of medicine liquid volume that most pharmaceutical factory adopts active carbon to add weight; The 2nd, active carbon itself does not have the depyrogenation activation.This research finds that also the heavy metal ion that active carbon brings, iron ion have oxidation harm to medicine; The auxilliary excipient of the lyophilized injection of prior art for preparing adopts low molecular dextran-40, this material has irritated effect to human body, the somebody is after having dripped several low molecular dextrans-40 transfusion, just produce anaphylaxis, the low molecular dextran amount-40 that is used as the excipient of Bei Leila azoles sodium has reached minimum hypersensitive, also have the general skeleton that adopts mannitol to make excipient, mannitol has the stimulation untoward reaction to blood vessel; The preparation of the Bei Leila azoles sodium of prior art does not protect Bei Leila azoles sodium making, storing transportation, use and entering intravital oxidation and the untoward reaction of this medicine that peroxidating, photooxidation cause.
Summary of the invention
For the defective of the Bei Leila azoles preparation of sodium that overcomes prior art for preparing, the invention provides a kind of composition of medicine and preparation technology thereof of Bei Leila azoles sodium.
One. Bei Leila azoles sodium composite medicine provided by the invention, by the combination of the material composition of following weight ratio:
Bei Leila azoles sodium: 5-10
Reduced glutathion and hepatocyte growth-promoting factors weight ratio
1: 10 compositions 20-30
Diammonium glycyrrhizinate 50-60
One. preparation technology:
1. use Bei Leila azoles sodium weight 100-120 water for injection doubly under normal speed stirs, respectively Bei Leila azoles sodium, reduced glutathion, hepatocyte growth-promoting factors, diammonium glycyrrhizinate are dissolved fully;
2. use through 180 ℃ of xeothermic removing in the composition of medicine medicinal liquid that former active carbon adds the preparation of the 1st step, it is 0.1% with the medicine liquid volume ratio that active carbon adds weight;
3. the composition of medicine medicinal liquid is 121 ℃ of moist heat sterilizations 20 minutes, treats that fluid temperature is 0.45 μ m with the upper strata in the time of 60-70 ℃, and lower floor is the two superimposed membrane filtration mistake of 0.22 μ m;
4. the composition of medicine medicinal liquid after sterilization filters to be cooled during to 10-15 ℃ with 8% sodium hydroxide solution adjust pH 7.8-8.0, through 0.05 μ m membrane filtration mistake; Ultrafilter membrane through molecular cut off 2000D filters again;
5. with 8% hydrochloric acid solution adjust pH 6.8-7.4, measure each constituent content of composition of medicine;
6. press the Bei Leila azoles sodium dosage that pharmaceutics allows, the aseptic subpackaged Bei Leila azoles sodium composite medicine injection of making;
7. or with the 5th step preparation compositions medicinal liquid, press the dosage of Bei Leila azoles sodium permission, aseptic subpackaged in cillin bottle, put into the freeze drying box of lyophilization unit, lyophilization routinely makes residual moisture in the composition of medicine solid≤2%.Tamponade, roll lid, make the lyophilized injection of Bei Leila azoles sodium composite medicine;
8. or with the 5th step prepare the composition of medicine medicinal liquid, aseptic subpackaged in 316L rustless steel pallet, lyophilization routinely makes moisture in the composition of medicine solid≤2%.The pharmaceutical preparation for preparing the dosage form such as enteric coatel tablets, enteric coated capsule, spray of the composition of medicine of Bei Leila azoles sodium more routinely.
Three. the advantage of Bei Leila azoles sodium composite medicine of the present invention has:
1. make excipient with what ammonium glycyrrhizinate did that excipient replaces prior art with low molecular dextran-40, both eradicated the anaphylaxis of low molecular dextran-40, but also brought the chronic hepatitis of the Glutamate pyruvate transaminase rises that ammonium glycyrrhizinate Zhi Beileila azoles causes, and alleviated of the effect of Bei Leila azoles sodium liver injury with the hepatocyte growth-promoting factors compound action.
2. add the protective effect of Reducing agent reduced glutathion, can eliminate the untoward reaction that Bei Leila azoles sodium brings in external and intravital photooxidation, oxidation, peroxidating greatly.Reduced glutathion and hepatocyte growth-promoting factors combination also have the drug allergy effect of anti-Bei Leila azoles sodium and promote by Bei Leila azoles sodium infringement liver cell regeneration effect.
3. adopt the technology depyrogenation of active carbon dosage to 0.1% through removing pyrogen and moisture, improve traditional active carbon depyrogenation technology, and, cross through the membrane filtration in 0.05 μ m aperture again and remove heavy metal ion, high price iron ion, active carbon fine particle through transferring medicinal liquid pH value 7.8-8.0 to make heavy metal ion, high price precipitation of iron ions complete; Ultrafilter membrane through molecular cut off 2000D filters again, molecular cut off is the above pyrogen molecule fragment of a 2000D residuals, originally discover, these materials are not adsorbed fully by active carbon and the pyrogen effect are arranged equally, without the activated carbon adsorption pyrogen, then to hold back ultrafiltration if directly hold back by some grades of molecular weight fractions with ultrafilter membrane, time-consuming, medicine redyes bacterium danger, and technology of the present invention makes medicine interior quality and big the raising.
4. all to be into the solid behind the true solution postlyophilization all be the molecularity dispersed system to all components, makes oral formulations, and each components contents uniformity is mixed than traditional coating and high-speed stirred wet mixing technology etc. will improve 20%.Aseptic rank and lyophilized injection peer.Therefore the preparation good process of compositions adjuvant scientific formula of the present invention and invention can be used as hydro-acupuncture preparation, lyophilized formulations, enteric coatel tablets and the capsule of the compositions medicine of alkalescence or neutral principal agent, the adjuvant component prescription of spray standard and the preparation technology of standard.
The specific embodiment
Embodiment 1
Bei Leila azoles sodium composite medicine provided by the invention, by the combination of the material composition of following weight ratio:
Bei Leila azoles sodium: 5
Reduced glutathion and hepatocyte growth-promoting factors weight ratio
Compositions 20 in 1: 10
Diammonium glycyrrhizinate 50
Preparation technology:
1. use Bei Leila azoles sodium weight 100-120 water for injection doubly under normal speed stirs, respectively Bei Leila azoles sodium, reduced glutathion, hepatocyte growth-promoting factors, diammonium glycyrrhizinate are dissolved fully;
2. use through 180 ℃ of xeothermic removing in the composition of medicine medicinal liquid that former active carbon adds the preparation of the 1st step, it is 0.1% with the medicine liquid volume ratio that active carbon adds weight;
3. the composition of medicine medicinal liquid is 121 ℃ of moist heat sterilizations 20 minutes, treats that fluid temperature is 0.45 μ m with the upper strata in the time of 60-70 ℃, and lower floor is the two superimposed membrane filtration mistake of 0.22 μ m;
4. the composition of medicine medicinal liquid after sterilization filters to be cooled during to 10-15 ℃ with 8% sodium hydroxide solution adjust pH 7.8-8.0, through 0.05 μ m membrane filtration mistake; Ultrafilter membrane through molecular cut off 2000D filters again;
5. with 8% hydrochloric acid solution adjust pH 6.8-7.4, measure each constituent content of composition of medicine;
6. press the Bei Leila azoles sodium dosage that pharmaceutics allows, the aseptic subpackaged Bei Leila azoles sodium composite medicine injection of making;
7. or with the 5th step preparation compositions medicinal liquid, press the dosage of Bei Leila azoles sodium permission, aseptic subpackaged in cillin bottle, put into the freeze drying box of lyophilization unit, lyophilization routinely makes residual moisture in the composition of medicine solid≤2%.Tamponade, roll lid, make the lyophilized injection of Bei Leila azoles sodium composite medicine;
8. or with the 5th step prepare the composition of medicine medicinal liquid, aseptic subpackaged in 316L rustless steel pallet, lyophilization routinely makes moisture in the composition of medicine solid≤2%.The pharmaceutical preparation for preparing the dosage form such as enteric coatel tablets, enteric coated capsule, spray of the composition of medicine of Bei Leila azoles sodium more routinely.
Embodiment 2:
Bei Leila azoles sodium composite medicine provided by the invention, by the combination of the material composition of following weight ratio:
Bei Leila azoles sodium: 10
Reduced glutathion and hepatocyte growth-promoting factors weight ratio
Compositions 30 in 1: 10
Diammonium glycyrrhizinate 60
Preparation technology:
1. use Bei Leila azoles sodium weight 100-120 water for injection doubly under normal speed stirs, respectively Bei Leila azoles sodium, reduced glutathion, hepatocyte growth-promoting factors, diammonium glycyrrhizinate are dissolved fully;
2. use through 180 ℃ of xeothermic removing in the composition of medicine medicinal liquid that former active carbon adds the preparation of the 1st step, it is 0.1% with the medicine liquid volume ratio that active carbon adds weight;
3. the composition of medicine medicinal liquid is 121 ℃ of moist heat sterilizations 20 minutes, treats that fluid temperature is 0.45 μ m with the upper strata in the time of 60-70 ℃, and lower floor is the two superimposed membrane filtration mistake of 0.22 μ m;
4. the composition of medicine medicinal liquid after sterilization filters to be cooled during to 10-15 ℃ with 8% sodium hydroxide solution adjust pH 7.8-8.0, through 0.05 μ m membrane filtration mistake; Ultrafilter membrane through molecular cut off 2000D filters again;
5. with 8% hydrochloric acid solution adjust pH 6.8-7.4, measure each constituent content of composition of medicine;
6. press the Bei Leila azoles sodium dosage that pharmaceutics allows, the aseptic subpackaged Bei Leila azoles sodium composite medicine injection of making;
7. or with the 5th step preparation compositions medicinal liquid, press the dosage of Bei Leila azoles sodium permission, aseptic subpackaged in cillin bottle, put into the freeze drying box of lyophilization unit, lyophilization routinely makes residual moisture in the composition of medicine solid≤2%.Tamponade, roll lid, make the lyophilized injection of Bei Leila azoles sodium composite medicine;
8. or with the 5th step prepare the composition of medicine medicinal liquid, aseptic subpackaged in 316L rustless steel pallet, lyophilization routinely makes moisture in the composition of medicine solid≤2%.The pharmaceutical preparation for preparing the dosage form such as enteric coatel tablets, enteric coated capsule, spray of the composition of medicine of Bei Leila azoles sodium more routinely.
Embodiment 3:
Bei Leila azoles sodium composite medicine provided by the invention, by the combination of the material composition of following weight ratio:
Bei Leila azoles sodium: 5
Reduced glutathion and hepatocyte growth-promoting factors weight ratio
Compositions 30 in 1: 10
Diammonium glycyrrhizinate 50
Preparation technology:
1. use Bei Leila azoles sodium weight 100-120 water for injection doubly under normal speed stirs, respectively Bei Leila azoles sodium, reduced glutathion, hepatocyte growth-promoting factors, diammonium glycyrrhizinate are dissolved fully;
2. use through 180 ℃ of xeothermic removing in the composition of medicine medicinal liquid that former active carbon adds the preparation of the 1st step, it is 0.1% with the medicine liquid volume ratio that active carbon adds weight;
3. the composition of medicine medicinal liquid is 121 ℃ of moist heat sterilizations 20 minutes, treats that fluid temperature is 0.45 μ m with the upper strata in the time of 60-70 ℃, and lower floor is the two superimposed membrane filtration mistake of 0.22 μ m;
4. the composition of medicine medicinal liquid after sterilization filters to be cooled during to 10-15 ℃ with 8% sodium hydroxide solution adjust pH 7.8-8.0, through 0.05 μ m membrane filtration mistake; Ultrafilter membrane through molecular cut off 2000D filters again;
5. with 8% hydrochloric acid solution adjust pH 6.8-7.4, measure each constituent content of composition of medicine;
6. press the Bei Leila azoles sodium dosage that pharmaceutics allows, the aseptic subpackaged Bei Leila azoles sodium composite medicine injection of making;
7. or with the 5th step preparation compositions medicinal liquid, press the dosage of Bei Leila azoles sodium permission, aseptic subpackaged in cillin bottle, put into the freeze drying box of lyophilization unit, lyophilization routinely makes residual moisture in the composition of medicine solid≤2%.Tamponade, roll lid, make the lyophilized injection of Bei Leila azoles sodium composite medicine;
8. or with the 5th step prepare the composition of medicine medicinal liquid, aseptic subpackaged in 316L rustless steel pallet, lyophilization routinely makes moisture in the composition of medicine solid≤2%.The pharmaceutical preparation for preparing the dosage form such as enteric coatel tablets, enteric coated capsule, spray of the composition of medicine of Bei Leila azoles sodium more routinely.
Embodiment 4:
Bei Leila azoles sodium composite medicine provided by the invention, by the combination of the material composition of following weight ratio:
Bei Leila azoles sodium: 10
Reduced glutathion and hepatocyte growth-promoting factors weight ratio
Compositions 20 in 1: 10
Diammonium glycyrrhizinate 60
Preparation technology:
1. use Bei Leila azoles sodium weight 100-120 water for injection doubly under normal speed stirs, respectively Bei Leila azoles sodium, reduced glutathion, hepatocyte growth-promoting factors, diammonium glycyrrhizinate are dissolved fully;
2. use through 180 ℃ of xeothermic removing in the composition of medicine medicinal liquid that former active carbon adds the preparation of the 1st step, it is 0.1% with the medicine liquid volume ratio that active carbon adds weight;
3. the composition of medicine medicinal liquid is 121 ℃ of moist heat sterilizations 20 minutes, treats that fluid temperature is 0.45 μ m with the upper strata in the time of 60-70 ℃, and lower floor is the two superimposed membrane filtration mistake of 0.22 μ m;
4. the composition of medicine medicinal liquid after sterilization filters to be cooled during to 10-15 ℃ with 8% sodium hydroxide solution adjust pH 7.8-8.0, through 0.05 μ m membrane filtration mistake; Ultrafilter membrane through molecular cut off 2000D filters again;
5. with 8% hydrochloric acid solution adjust pH 6.8-7.4, measure each constituent content of composition of medicine;
6. press the Bei Leila azoles sodium dosage that pharmaceutics allows, the aseptic subpackaged Bei Leila azoles sodium composite medicine injection of making;
7. or with the 5th step preparation compositions medicinal liquid, press the dosage of Bei Leila azoles sodium permission, aseptic subpackaged in cillin bottle, put into the freeze drying box of lyophilization unit, lyophilization routinely makes residual moisture in the composition of medicine solid≤2%.Tamponade, roll lid, make the lyophilized injection of Bei Leila azoles sodium composite medicine;
8. or with the 5th step prepare the composition of medicine medicinal liquid, aseptic subpackaged in 316L rustless steel pallet, lyophilization routinely makes moisture in the composition of medicine solid≤2%.The pharmaceutical preparation for preparing the dosage form such as enteric coatel tablets, enteric coated capsule, spray of the composition of medicine of Bei Leila azoles sodium more routinely.
Embodiment 5:
Bei Leila azoles sodium composite medicine provided by the invention, by the combination of the material composition of following weight ratio:
Bei Leila azoles sodium: 8
Reduced glutathion and hepatocyte growth-promoting factors weight ratio
Compositions 26 in 1: 10
Diammonium glycyrrhizinate 57
Preparation technology:
1. use Bei Leila azoles sodium weight 100-120 water for injection doubly under normal speed stirs, respectively Bei Leila azoles sodium, reduced glutathion, hepatocyte growth-promoting factors, diammonium glycyrrhizinate are dissolved fully;
2. use through 180 ℃ of xeothermic removing in the composition of medicine medicinal liquid that former active carbon adds the preparation of the 1st step, it is 0.1% with the medicine liquid volume ratio that active carbon adds weight;
3. the composition of medicine medicinal liquid is 121 ℃ of moist heat sterilizations 20 minutes, treats that fluid temperature is 0.45 μ m with the upper strata in the time of 60-70 ℃, and lower floor is the two superimposed membrane filtration mistake of 0.22 μ m;
4. the composition of medicine medicinal liquid after sterilization filters to be cooled during to 10-15 ℃ with 8% sodium hydroxide solution adjust pH 7.8-8.0, through 0.05 μ m membrane filtration mistake; Ultrafilter membrane through molecular cut off 2000D filters again;
5. with 8% hydrochloric acid solution adjust pH 6.8-7.4, measure each constituent content of composition of medicine;
6. press the Bei Leila azoles sodium dosage that pharmaceutics allows, the aseptic subpackaged Bei Leila azoles sodium composite medicine injection of making;
7. or with the 5th step preparation compositions medicinal liquid, press the dosage of Bei Leila azoles sodium permission, aseptic subpackaged in cillin bottle, put into the freeze drying box of lyophilization unit, lyophilization routinely makes residual moisture in the composition of medicine solid≤2%.Tamponade, roll lid, make the lyophilized injection of Bei Leila azoles sodium composite medicine;
8. or with the 5th step prepare the composition of medicine medicinal liquid, aseptic subpackaged in 316L rustless steel pallet, lyophilization routinely makes moisture in the composition of medicine solid≤2%.The pharmaceutical preparation for preparing the dosage form such as enteric coatel tablets, enteric coated capsule, spray of the composition of medicine of Bei Leila azoles sodium more routinely.
The pharmacodynamics demonstration test:
1. animal is selected:
Rat commonly used.Should be healthy, male or female will be indicated kind system and the quality certification number of animal.10 of every group of rats, rat body weight 200-250g.
2. model and method:
2.1 acetic acid burns type gastric ulcer model laboratory animal and selects rat, fasting is 24 hours before the experiment, freely drink water, under etherization open the abdominal cavity, the glass tubing of internal diameter 5mm, long 30mm vertically is positioned on the body of stomach serosal surface, ice acetic acid 0.2ml in tube chamber dipped in out glacial acetic acid with cotton swab after 1.5 minutes, the suture operation otch.The postoperative normal diet was set up matched group and administration group in second day at random.Successive administration 15 days.Dissect and take out stomach and use formaldehyde fixed, measure the ulcer area, compare between each group.
2.2 pyloric ligation ulcers gastric ulcer model rat, male and female dual-purpose, random packet, animal fasting 36-72 hour is freely drunk water, with ether with Animal Anesthesia, open the abdominal cavity, the ligation pylorus, postoperative was dissected and is got stomach in 18 hours, injected 1% formalin 8ml in gastral cavity, stomach is immersed in 1% formalin solution, after 10 minutes, cut off stomach along greater gastric curvature, the stomach ulcer surface is long-pending before the counting.
The embodiment result of the test:
Embodiment 1 result of the test:
Embodiment 2 result of the tests:
Embodiment 3 result of the tests:
Embodiment 4 result of the tests:
Embodiment 5 result of the tests:
According to preferred embodiment; the present invention is described; should be understood that: the description of front and embodiment are just to explanation the present invention; under prerequisite without departing from the spirit and scope of the present invention; those skilled in the art can design multiple replacement scheme of the present invention; and improvement project, it all should be understood to be in protection scope of the present invention.
Claims (5)
1. Bei Leila azoles sodium composite medicine provided by the invention is characterized in that, by the raw material of following weight ratio
The composition combination:
Bei Leila azoles sodium: 5-10
Reduced glutathion and hepatocyte growth-promoting factors weight ratio
1: 10 compositions 20-30
Diammonium glycyrrhizinate 50-60
Preparation technology:
(1) uses Bei Leila azoles sodium weight 100-120 water for injection doubly under normal speed stirs, respectively Bei Leila azoles sodium, reduced glutathion, hepatocyte growth-promoting factors, diammonium glycyrrhizinate are dissolved fully;
(2) use through 180 ℃ of xeothermic removing in the composition of medicine medicinal liquid that former active carbon adds the preparation of the 1st step, it is 0.1% with the medicine liquid volume ratio that active carbon adds weight;
(3) the composition of medicine medicinal liquid is 121 ℃ of moist heat sterilizations 20 minutes, treats that fluid temperature is 0.45 μ m with the upper strata in the time of 60-70 ℃, and lower floor is the two superimposed membrane filtration mistake of 0.22 μ m;
(4) the composition of medicine medicinal liquid after sterilization filters to be cooled during to 10-15 ℃ with 8% sodium hydroxide solution adjust pH 7.8-8.0, through 0.05 μ m membrane filtration mistake; Ultrafilter membrane through molecular cut off 2000D filters again;
(5), measure each constituent content of composition of medicine with 8% hydrochloric acid solution adjust pH 6.8-7.4;
2. according to the described Bei Leila azoles of claim 1 sodium composite medicine, it is characterized in that, press the Bei Leila azoles sodium dosage that pharmaceutics allows, the aseptic subpackaged Bei Leila azoles sodium composite medicine injection of making;
3. according to the described Bei Leila azoles of claim 1 composition of medicine, it is characterized in that or with (5) step preparation compositions medicinal liquid, press the dosage that Bei Leila azoles sodium allows, aseptic subpackaged in cillin bottle, put into the freeze drying box of lyophilization unit, lyophilization routinely makes residual moisture in the composition of medicine solid≤2%.Tamponade, roll lid, make the lyophilized injection of Bei Leila azoles sodium composite medicine;
4. according to the described Bei Leila azoles of claim 1 sodium composite medicine, it is characterized in that, or with (5) step preparation composition of medicine medicinal liquid, aseptic subpackaged in 316L rustless steel pallet, lyophilization routinely makes moisture in the composition of medicine solid≤2%.The pharmaceutical preparation for preparing the dosage form such as enteric coatel tablets, enteric coated capsule, spray of the composition of medicine of Bei Leila azoles sodium more routinely;
5. according to the described Bei Leila azoles of claim 1 sodium composite medicine, it is characterized in that, be used for the treatment of the medicine of gastric ulcer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106074231A CN102091070A (en) | 2010-12-27 | 2010-12-27 | Rabeprazole sodium combined medicament and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106074231A CN102091070A (en) | 2010-12-27 | 2010-12-27 | Rabeprazole sodium combined medicament and preparation process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102091070A true CN102091070A (en) | 2011-06-15 |
Family
ID=44124450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010106074231A Pending CN102091070A (en) | 2010-12-27 | 2010-12-27 | Rabeprazole sodium combined medicament and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102091070A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631842A (en) * | 2012-04-12 | 2012-08-15 | 江苏久吾高科技股份有限公司 | Method for removing endotoxin in biological pharmaceutical preparations |
| CN104056247A (en) * | 2013-03-20 | 2014-09-24 | 长春海悦药业有限公司 | Pharmaceutical composition containing hepatocyte growth promoting factor and preparation thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101627996A (en) * | 2009-08-20 | 2010-01-20 | 山东罗欣药业股份有限公司 | Rabeprazole sodium composition and preparation method thereof |
| CN101766614A (en) * | 2010-01-11 | 2010-07-07 | 蔡海德 | Omeprazole sodium combined medicament and preparation method thereof |
-
2010
- 2010-12-27 CN CN2010106074231A patent/CN102091070A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101627996A (en) * | 2009-08-20 | 2010-01-20 | 山东罗欣药业股份有限公司 | Rabeprazole sodium composition and preparation method thereof |
| CN101766614A (en) * | 2010-01-11 | 2010-07-07 | 蔡海德 | Omeprazole sodium combined medicament and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 谢建康 等: "注射用雷贝拉唑钠的制备及安全性评价", 《中国现代应用药学杂志》, vol. 26, no. 5, 31 May 2009 (2009-05-31), pages 385 - 387 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631842A (en) * | 2012-04-12 | 2012-08-15 | 江苏久吾高科技股份有限公司 | Method for removing endotoxin in biological pharmaceutical preparations |
| CN102631842B (en) * | 2012-04-12 | 2014-09-10 | 江苏久吾高科技股份有限公司 | Method for removing endotoxin in biological pharmaceutical preparations |
| CN104056247A (en) * | 2013-03-20 | 2014-09-24 | 长春海悦药业有限公司 | Pharmaceutical composition containing hepatocyte growth promoting factor and preparation thereof |
| CN104056247B (en) * | 2013-03-20 | 2016-03-02 | 长春海悦药业有限公司 | A kind of pharmaceutical composition and preparation thereof containing hepatocyte growth-promoting factors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102058593A (en) | Combination medicament of ilaprazole sodium and preparation process thereof | |
| CN102218035A (en) | Formula of combined medicament of esomeprazole sodium liposomes, method for preparing same and application thereof | |
| CN101744815B (en) | Composite medicament of omeprazole sodium | |
| US11491138B2 (en) | Injectable psychoactive alkaloid composition and preparation thereof | |
| CN102657650A (en) | Esomeprazole sodium lyophilized powder composition for injection and preparation method thereof | |
| CN101513387A (en) | Esomeprazole magnesium injection liquid | |
| CN101766614A (en) | Omeprazole sodium combined medicament and preparation method thereof | |
| CN102091070A (en) | Rabeprazole sodium combined medicament and preparation process thereof | |
| CN101317846B (en) | Tetrodotoxin formulation for drug rehabilitation , pain ease | |
| CN103961322B (en) | A kind of injection Dexlansoprazole freeze-dried composition and preparation method thereof | |
| CN101766615B (en) | Pantoprazole sodium combined drug | |
| CN105125507B (en) | A kind of Esomeprazole sodium injection freezes compound powder and preparation method thereof | |
| KR20100031069A (en) | Mastic extracts and preparation thereof | |
| CN105456528A (en) | Suppository for treating gynecological inflammation and preparation method thereof | |
| CN101891751A (en) | Method for preparing tetrodotoxin | |
| US20190160126A1 (en) | Compositions and methods for treating reproductive indicators symptomatic of male infertility | |
| CN103933100A (en) | Preparation method of total alkaloid of Chinese mahonia stem and applications of total alkaloid of Chinese mahonia stem in preparation of drugs for preventing and treating gastric ulcer | |
| CN103263415A (en) | Levo pantoprazole sodium composition for injection and preparation method thereof | |
| CN107982261B (en) | Esomeprazole sodium freeze-dried powder and preparation method thereof | |
| KR101756149B1 (en) | A composition for treating gastric ulcer comprising the extract of Inula britannica | |
| CN105147624A (en) | Esomeprazole sodium for injection and preparation method thereof | |
| CN106266023B (en) | Medicine for treating gastric ulcer and preparation method thereof | |
| CN101768156A (en) | Pidotimod arginine salt and preparation thereof | |
| CN102670529A (en) | Levo-pantoprazole sodium freeze-dried powder composition for injection and preparation method thereof | |
| CN101773501A (en) | Pantoprazole sodium combined medicament and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110615 |